San Diego, July 28, 2025 - SeekIn Inc., a leader in blood-based early cancer detection and monitoring technologies, today announced it has received authorization for five U.S. trademarks, further expanding its robust global intellectual property portfolio. The newly registered trademarks—SeekInCare® (blood-based pan-cancer early detection test), OncoSeek® (blood-based, low-cost multi-cancer early detection test), SeekInClarity® (blood-based pan-cancer treatment response monitoring test), LeukoPrint® (molecular karyotyping test for hematologic malignancies), and PanCanSeek® (precision diagnosis and therapeutic guidance for hematologic malignancies)—mark a significant milestone following successful trademark registrations in China and the European Union.
“These latest U.S. trademark authorizations strengthen SeekIn’s commitment to innovation and quality as we introduce the next generation of non-invasive cancer diagnostics,” said Dr. Mao Mao, Founder & CEO at SeekIn Inc. “Securing these marks across key global markets not only affirms the uniqueness of our solutions, but also positions us for continued growth as we strive to make accessible, accurate early cancer detection and personalized monitoring available to more patients worldwide.”
With these newly secured U.S. trademarks, SeekIn is poised to expand its presence and enhance its service offerings in the American market, while leveraging established approvals in China and the EU to accelerate international growth.
For more information about SeekIn’s solutions and partnerships, visit www.seekincancer.com.